Bichler A, Fuchs D, Hausen A, Hetzel H, König K, Wachter H
Clin Biochem. 1982 Feb;15(1):38-40. doi: 10.1016/s0009-9120(82)90421-0.
Urinary neopterine values in 96 healthy women were compared with those in a group of 63 patients with cancer of the genitals who had not yet undergone treatment. Significantly higher median neopterine levels were found in the patients with carcinoma (p less than 0.001). In the 63 cancer patients who had not yet been treated, the diagnosis was made correctly in 65% of the cases by monitoring neopterine levels. In the follow-up of 72 patients with cancer of the genitals in 74% the neopterine values corresponded with the clinico-roentgenological findings. In 22%, false positive neopterine values (no recurrence of the tumor), and in 4% false negative values (recurrence, or progression of the carcinoma) were observed. These results confirm previous reports concerning the significance of pteridine excretion in patients with cancer. However, more investigations have to be performed to establish the value of neopterine sampling in monitoring patients with malignant tumors.
对96名健康女性的尿新蝶呤值与63名尚未接受治疗的生殖器癌症患者的尿新蝶呤值进行了比较。发现癌症患者的中位新蝶呤水平显著更高（p<0.001）。在63名尚未接受治疗的癌症患者中，通过监测新蝶呤水平，65%的病例诊断正确。在对72名生殖器癌症患者的随访中，74%的新蝶呤值与临床-放射学检查结果相符。观察到22%的患者新蝶呤值为假阳性（肿瘤无复发），4%为假阴性（癌症复发或进展）。这些结果证实了先前关于癌症患者蝶啶排泄意义的报道。然而，还需要进行更多研究以确定新蝶呤采样在监测恶性肿瘤患者中的价值。
